Literature DB >> 23474633

PET/CT imaging in neuroblastoma.

A Piccardo1, E Lopci, M Conte, L Foppiani, A Garaventa, M Cabria, G Villavecchia, S Fanti, A Cistaro.   

Abstract

123Iodine-metaiodobenzylguanidine (123I-MIBG) scintigraphy is currently the tracer of choice for neuroblastoma (NB). It has high diagnostic accuracy and prognostic value for the assessment of patients after chemotherapy. A positive 123I-MIBG scan is also used for the basis of targeted radionuclide therapy with 131I-MIBG. I-123 MIBG scan however has some limitations which should be taken into account. Moreover the reasons for false negative MIBG results have not been entirely elucidated. Meticulous correlation with radiological examinations and recognition of the normal distribution pattern of 123I-MIBG in children is vital to obtain optimal results. With its technical superiorities, positron emission tomography/computed tomography (PET/CT) can be successfully introduced into the diagnostic workup of NB. Different PET tracers have been offered for imaging in patients with NB, and the efficacy of this modality has been compared with that of 123I-MIBG scan. Our review aims to analyze the present role of PET/CT imaging and radiopharmaceuticals in NB.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23474633

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN： 1824-4785            Impact factor:   2.346


  8 in total

1.  Brain Metastasis from Neuroblastoma Depicted by (18)F-DOPA PET/CT.

Authors:  Arnoldo Piccardo; Giovanni Morana; Michela Massollo; Marco Pescetto; Massimo Conte; Alberto Garaventa
Journal:  Nucl Med Mol Imaging       Date:  2015-02-03

2.  Guidelines on nuclear medicine imaging in neuroblastoma.

Authors:  Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10       Impact factor: 9.236

3.  Comparison of effective radiation doses from X-ray, CT, and PET/CT in pediatric patients with neuroblastoma using a dose monitoring program.

Authors:  Yeun Yoon Kim; Hyun Joo Shin; Myung Joon Kim; Mi-Jung Lee
Journal:  Diagn Interv Radiol       Date:  2016 Jul-Aug       Impact factor: 2.630

4.  Clinical Significance of Pretreatment FDG PET/CT in MIBG-Avid Pediatric Neuroblastoma.

Authors:  Seo Young Kang; Muhammad Kashif Rahim; Yong-Il Kim; Gi Jeong Cheon; Hyoung Jin Kang; Hee Young Shin; Keon Wook Kang; June-Key Chung; E Edmund Kim; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2016-10-06

Review 5.  123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Authors:  Gitta Bleeker; Godelieve A M Tytgat; Judit A Adam; Huib N Caron; Leontien C M Kremer; Lotty Hooft; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29

Review 6.  Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

Authors:  Jia Xia; Hang Zhang; Qun Hu; Shuang-You Liu; Liu-Qing Zhang; Ai Zhang; Xiao-Ling Zhang; Ya-Qin Wang; Ai-Guo Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-10-20

7.  18Fluorine-fluorodeoxyglucose PET/CT Imaging in Childhood Malignancies

Authors:  Nilüfer Bıçakçı; Murat Elli
Journal:  Mol Imaging Radionucl Ther       Date:  2021-02-09

8.  Usefulness of positron emission tomography in the differentiation between tumor and infectious lesions in pediatric oncology: a case report.

Authors:  Fernanda Rodrigues Tibúrcio; Karla Emília de Sá Rodrigues; Hérika Martins Mendes Vasconcelos; Débora Marques Miranda; Ana Cristina Simões e Silva
Journal:  BMC Pediatr       Date:  2015-09-03       Impact factor: 2.125
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.